Pharmaceutical Excipients Market, Global, 2024–2030

Report Summary: Pharmaceutical Excipients Market, Global, 2024–2030

The global pharmaceutical excipients market size was valued at USD 10.42 billion in 2024 and is expected to reach USD 13.62 billion by 2030, expanding at a CAGR of 4.6% (2024–2030). Market growth is driven by the rising burden of chronic diseases, increased consumption of prescription and generic medicines, strong biologics pipeline expansion, and accelerating pharmaceutical manufacturing across North America, Europe, and Asia-Pacific. The increasing adoption of advanced drug formulations—oral, injectable, inhalable, topical, and ophthalmic—is further stimulating excipient demand across global markets.

Key Market Trends & Insights

• North America accounted for the largest revenue share in 2024, supported by the world’s highest per-capita drug consumption and strong biologics manufacturing.
• Oral excipients dominated the market with USD 6.06 billion in 2024, driven by high demand for tablets, capsules, ODTs, and chewable formats.
• Injectable excipients reached USD 2.46 billion in 2024, expanding rapidly due to biologics, mRNA vaccines, CGT therapies, and oncology drug pipelines.
• Inhalable excipients registered the fastest growth rate, supported by rising COPD, asthma prevalence, and increased adoption of DPIs, MDIs, and nasal sprays.
• APAC emerged as the fastest-growing region, led by China and India’s large pharmaceutical manufacturing bases and growing generic drug output.
• Growing demand for solubility-enhancing, controlled-release, mucoadhesive, and viscosity-modifying excipients continues to shape the innovation landscape.

Market Size & Forecast

Total Market Value

• 2024 Market Size: USD 10.42 Billion
• 2030 Projected Market Size: USD 13.62 Billion
• CAGR (2024–2030): 4.6%

Market Overview: Pharmaceutical Excipients Market, Global, 2024–2030

The pharmaceutical excipients market continues to evolve from a traditionally commodity-based sector into a critical enabler of modern drug formulation. As APIs become increasingly complex—with challenges such as poor solubility, instability, high potency, and variable bioavailability—manufacturers are relying on advanced excipients to ensure consistent therapeutic performance. Oral solid dosage forms remain the dominant application area, but growth momentum is shifting toward patient-centric formats including ODTs, chewables, controlled-release systems, and taste-masked formulations. These trends are increasing demand for high-functionality binders, co-processed excipients, solubility enhancers, and film-coating materials.

The biopharmaceutical excipients market is expanding even faster as the global biologics pipeline accelerates. Biologic and biosimilar products—such as monoclonal antibodies, fusion proteins, vaccines, and emerging modalities like mRNA and CGT—require specialized excipients that can stabilize proteins, control viscosity, prevent aggregation, and maintain structural integrity during manufacturing, shipment, and storage. This shift is driving significant adoption of high-purity sugars, buffers, surfactants, polymers, and lipid-based systems.

Across both segments, regulatory tightening, quality-by-design requirements, and the standardization of excipient performance criteria are elevating expectations for purity, consistency, and documentation. Meanwhile, the rapid expansion of pharmaceutical and biopharmaceutical manufacturing in Asia-Pacific, the Middle East, and Latin America is creating new growth pockets, especially for generics and biosimilars.

Overall, the global excipients ecosystem is transitioning toward innovation-led, performance-driven materials that play an essential role in the success of next-generation drug delivery systems.

Scope of Analysis: Pharmaceutical Excipients Market, Global, 2024–2030

This analysis examines the global pharmaceutical excipients market and its rapidly expanding biologics-focused counterpart, the biopharmaceutical excipients market, providing a comprehensive view of how excipients support the development, stability, and delivery performance of modern drug formulations. The study evaluates market dynamics across the 2022–2030 period, with 2024 as the base year, and offers detailed insights into trends shaping demand across oral, injectable, topical, inhalation, and ophthalmic dosage forms.

The assessment includes functional categories such as binders, fillers, coatings, disintegrants, solubilizers, stabilizers, surfactants, buffering agents, preservatives, lipid-based systems, polymer carriers, and co-processed multifunctional excipients. Special emphasis is placed on excipients designed for biologics, biosimilars, mRNA vaccines, and other advanced therapeutic modalities, as these segments are redefining performance and purity requirements within the market.

Geographically, the analysis covers North America, Europe, Asia-Pacific, and LAMEA, with a focus on regional manufacturing capabilities, regulatory expectations, and therapeutic demand patterns. The study also evaluates how growing chronic disease prevalence, expansion of generics and biosimilars, and increased R&D activity are influencing excipient consumption globally.

In addition, the scope includes competitive benchmarking, supplier strategies, innovation pipelines, and supply-chain considerations that affect excipient availability and adoption. Overall, this analysis provides a structured and forward-looking view of the global excipients landscape.

Revenue & Spending Forecast : Pharmaceutical Excipients Market, Global, 2024–2030

The pharmaceutical excipients market continues to show stable long-term expansion. Global revenue is expected to increase from USD 9.46 billion in 2022 to around USD 10.42 billion in 2024, supported by sustained demand for oral and injectable formulations. By 2030, the market is projected to reach approximately USD 13.62 billion, driven by the rising adoption of advanced drug delivery systems, increased biologics production, and broader use of high-functionality excipients. This trajectory reflects a healthy CAGR of 4.6% during 2024–2030, underscoring consistent, formulation-led growth across both mature and emerging pharmaceutical markets.

Growth Drivers: Pharmaceutical Excipients Market, Global, 2024–2030

Growth in the pharmaceutical excipients market is strongly supported by rising global medicine consumption, expansion of chronic disease treatments, and the development of increasingly complex drug formulations. As active pharmaceutical ingredients become more potent and less soluble, the need for advanced excipients that improve bioavailability, stability, and manufacturability continues to accelerate. This includes higher adoption of solubility enhancers, co-processed multifunctional excipients, film coatings, and controlled-release systems used across tablets, capsules, and orally disintegrating formats.

In parallel, the biopharmaceutical excipients market is expanding rapidly due to the surge in biologics, biosimilars, mRNA therapies, and high-concentration injectable formulations. These therapies demand high-purity stabilizers, surfactants, buffers, sugars, and lipid systems capable of preserving protein integrity and preventing aggregation during manufacturing, transportation, and storage.

Additional growth momentum comes from increasing patient preference for easy-to-administer dosage forms, ongoing advancements in materials science, and growing pharmaceutical manufacturing capacity in emerging economies. Regulatory agencies are also encouraging higher-quality excipients with defined performance attributes, pushing manufacturers to invest in innovation and next-generation formulation tools.

Growth Restraints: Pharmaceutical Excipients Market, Global, 2024–2030

Despite its steady expansion, the pharmaceutical excipients market faces several constraints that impact development timelines and adoption. One of the most significant challenges is the lack of a dedicated regulatory approval pathway for novel excipients, which slows innovation and pushes manufacturers toward repurposed or co-processed versions of existing materials. This makes it difficult to introduce entirely new chemistries that could support emerging drug technologies.

Supply chain complexity also remains a key restraint. Many excipients depend on raw materials sourced from limited suppliers or specific geographic regions, exposing manufacturers to volatility in pricing, transportation, and availability. Consistency in quality and compliance is critical, and meeting global pharmacopeial standards requires significant investment in documentation, analytical testing, and validation.

For the biopharmaceutical excipients market, technical challenges are even higher. Biologics and mRNA therapies are extremely sensitive to pH, temperature, and mechanical stress, placing greater performance requirements on stabilizers and surfactants. Manufacturers must balance safety, purity, and functionality without compromising therapeutic efficacy—making excipient design and selection more complex.

Economic pressures, margin constraints, and increasing regulatory scrutiny further contribute to slower adoption of advanced or premium excipients across price-sensitive regions.

Competitive Landscape: Pharmaceutical Excipients Market, Global, 2024–2030

The global pharmaceutical excipients market is moderately fragmented, with a mix of multinational chemical companies, specialized excipient developers, and regionally focused suppliers. Competition is shaped by product quality, regulatory compliance, innovation capability, global distribution reach, and technical support offered to formulation teams.

Major companies operating in the space include:
BASF SE, Evonik Industries, Ashland, Lubrizol Corporation, Roquette, Avantor, DFE Pharma, Kerry Group, JRS Pharma, Gattefossé, Merck KGaA, Croda International, and Pfanstiehl.
These firms maintain strong portfolios across oral solids, injectables, topical systems, and emerging biologic-focused excipients.

A significant area of competition involves high-purity excipients for injectables, driven by the expansion of the biopharmaceutical excipients market. Suppliers offering advanced lipid systems, high-grade sugars, surfactants, polymers, and buffer solutions are increasingly sought after due to the rising volume of monoclonal antibodies, biosimilars, and mRNA-based vaccines.

Companies are also investing in co-processed excipients that enhance flowability, compressibility, and solubility—allowing formulators to reduce processing steps and improve product performance. Strategic acquisitions, joint ventures, and partnerships with CDMOs (Contract Development & Manufacturing Organizations) are becoming common, as they help strengthen innovation pipelines and expand access to global pharmaceutical customers.

Competitive differentiation is heavily influenced by the ability to meet stringent regulatory standards, deploy robust quality systems, and support customers with formulation expertise. As the market shifts toward complex APIs and biologics, suppliers with strong R&D capabilities and biologic-compatible excipient technologies are positioned to experience stronger long-term growth.